Objective To investigate the effect of carvedilol on cardiac function and myocardial injury in non-myocardial infarction patients with coronary heart disease and angina pectoris. Methods A total of 120 non-myocardial infarction patients with coronary heart disease and angina pectoris admitted to the Zunhua People's Hospital from Jan. 2014 to May 2017 were selected and divided into the study group and the control group according to the random number table method, 60 cases in each group. The patients in the two groups were treated with conventional drugs, on this basis, the patients in the study group were treated with Carvedilol Tablets. Both groups were continuously treated for three months. Results In the study group, one case voluntarily dropped out and two cases were lost to follow-up. In the control group, one case was lost to follow-up and one case was missing clin. evaluation data. The clin. data of the above patients were excluded. The total effective rate of the study group was 91. 23%, which was significantly higher than77. 59% of the control group(P < 0. 05). After treatment, the frequency of angina pectoris, numeric rating scales( NRS) score, QT interval dispersion(QTd), levels of cardiac troponin T( cTnT), creatine kinase-MB( CK-MB) and myeloperoxidase( MPO) in the study group were significantly lower than those in the control group, the left ventricular end-systolic diameter( LVESd) and left ventricular end-diastolic diameter(LVEDd)in the study group were significantly shorter than those in the control group, and the 6-min walking distance(6 MWD)in the study group was significantly longer than that in the control group, and the left ventricular ejection fraction(LVEF)in the study group was significantly higher than that in the control group(P < 0. 05). During the treatment, the incidence of adverse reactions in the study group was similar to that in the control group(15. 79% vs. 10. 34%, P > 0. 05). Conclusion On the basis of conventional drug therapy, carvedilol has a certain effect in the treatment of non-myocardial infarction patients with coronary heart disease and angina pectoris, which can reduce the frequency and pain degree of angina pectoris, improve the cardiac function, myocardial injury index and prognosis.